Product Description
LOXO-338 blocks the activity of BCL-2, a protein that contributes to cancer cell growth. By blocking this protein, LOXO-338 may stop the growth of certain B-cell lymphomas. It is taken orally (by mouth). (Sourced from: https://www.mskcc.org/cancer-care/clinical-trials/21-448)
Mechanisms of Action: BCL2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: Eastern America
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Italy, Poland, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma|Multiple Myeloma|Waldenstrom Macroglobulinemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05024045 |
LOXO-BCL-20001 | P1 |
Active, not recruiting |
Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Multiple Myeloma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|B-Cell Marginal Zone Lymphoma |
2023-06-14 |
12% |
2024-05-31 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/11/2023 |
News Article |
Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting |
|
03/10/2021 |
News Article |
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR) |